Ebola virus (EBOV) gained public notoriety in the last decade largely as a consequence of the highly publicised isolation of a new EBOV species in a suburb of Washington, DC, in 1989, together with the dramatic clinical presentation of EBOV infection and high case-fatality rate in Africa (near 90% in some outbreaks), and the unusual and striking morphology of the virus. Furthermore, there are no vaccines or effective therapies currently available. Progress in understanding the origins of the pathophysiological changes that make EBOV infections of humans so devastating has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the mechanisms of EBOV pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. Notably, identifying factors triggering the haemorrhagic complications that characterise EBOV infections led to the development of a strategy to modulate coagulopathy; this therapeutic modality successfully mitigated the effects of EBOV haemorrhagic fever in nonhuman primates. This review summarises our current understanding of EBOV pathogenesis and discusses various approaches to therapeutic intervention based on our current understanding of how EBOV produces a lethal infection.
Ebola virus (EBOV) infections are usually the most severe of those caused by the viruses of lethal haemorrhagic disease in humans. Clinical symptoms appear suddenly after an incubation period of 2 to 21 days (Ref. 1) . Common presenting complaints include high fever, chills, malaise and myalgia (Refs 2, 3, 4, 5, 6, 7). As the disease progresses, there is evidence of multisystemic involvement, and manifestations include prostration, anorexia, vomiting, nausea, abdominal pain, diarrhoea, shortness of breath, sore throat, oedema, confusion and coma (Refs 2, 3, 4, 5, 6, 7). Abnormalities in blood coagulation and fibrinolysis are manifested as petechiae, ecchymoses, mucosal haemorrhages, and uncontrolled bleeding at venipuncture sites (Refs 2, 3, 4, 5, 6, 7); however, massive loss of blood is atypical and, when present, is largely restricted to the gastrointestinal tract. In fact, even in these cases, blood volume loss is insufficient to account for death. The presence of a maculopapular rash is a prominent feature (Refs 2, 3, 4, 5, 6, 7), but is not pathognomonic for EBOV haemorrhagic fever (HF). Fulminant EBOV infection typically evolves to shock, convulsions, and, in most cases, diffuse coagulopathy (Refs 2, 3, 4, 5, 6, 7). Death usually occurs 6-9 days after the onset of clinical symptoms. It should be noted that evidence of asymptomatic EBOV infection was documented in a small group of individuals during a recent outbreak (Ref. 8) , but the clinical and epidemiological relevance of this observation is uncertain.
Epidemiology
EBOV was first recognised during nearsimultaneous explosive outbreaks in 1976 in small communities in the former Zaire [now the Democratic Republic of the Congo (DRC)] (Ref. 6) and Sudan (Ref. 5). There was significant secondary transmission through reuse of unsterilised needles and syringes, and nosocomial contacts. These independent outbreaks involved serologically distinct viral species: Zaire EBOV (ZEBOV) and Sudan EBOV (SEBOV). The ZEBOV outbreak involved 318 cases and 280 deaths (88% mortality), while the SEBOV outbreak involved 284 cases and 151 deaths (53% mortality). Since 1976, EBOV has appeared sporadically in Africa, causing several small to mid-size outbreaks between 1976 and 1979. In 1995, there was a large epidemic of ZEBOV HF involving 315 cases, with an 81% case fatality rate, in Kikwit, a community in the former Zaire (Ref. 1) . Meanwhile, between 1994 and 1996, there were smaller outbreaks caused by ZEBOV in Gabon (Ref. 9 ). More recently, Uganda, Gabon and the DRC suffered large epidemics of viral HF attributed to EBOV. The most recent outbreak in the DRC also involved a catastrophic decline in populations of great apes, which are thought to have a role in transmission to humans (Ref. 10) .
In 1989, a third species of EBOV, Reston EBOV (REBOV), appeared in Reston, VA, USA, in association with an outbreak of viral HF among cynomolgus monkeys (Macaca fascicularis) imported to the USA from the Philippine Islands (Ref. 11) . Hundreds of monkeys were infected (with high mortality) in this episode, but no human cases occurred (although four animal caretakers seroconverted without overt disease). Epizootics in cynomolgus monkeys recurred at other facilities in the USA and Europe through 1992, and again in 1996. A fourth species of EBOV, Ivory Coast EBOV (ICEBOV), was identified in Côte d'Ivoire in 1994; this species was associated with chimpanzees and only one (nonfatal) human infection was identified (Ref. 12) .
Very little is known about the natural history of EBOV. Implication of animal reservoirs and arthropod vectors has been aggressively sought without success. (See Ref. 13 for a more detailed discussion of the epidemiology of EBOV.) Taxonomy EBOV belongs to the family Filoviridae, which comprises filamentous, enveloped, nonsegmented, negative-sense RNA viruses (reviewed in Ref. 13 ; see also http://www.ncbi.nlm.nih.gov/ICTV). The family Filoviridae is divided into two genera: Marburgvirus and Ebolavirus. The Marburgvirus genus contains a single species: Lake Victoria marburg virus (LVMARV). The Ebolavirus genus consists of the four species of EBOV discussed above: ZEBOV, SEBOV, REBOV and ICEBOV.
EBOV: structure and protein functions
EBOV particles contain an ~19 kb, single negative-stranded, linear RNA genome that is noninfectious. The genome encodes seven structural proteins, with a gene order of: 3' leader, nucleoprotein (NP), virion protein (VP) 35 (VP35), VP40, glycoprotein (GP), VP30, VP24, polymerase L protein, and 5' trailer (Ref. 14) . Four of these proteins -NP, VP30, VP35 and L -associate with the genomic RNA in a ribonucleoprotein complex, while the three remaining proteins (GP, VP24 and VP40) are associated with the membrane. GP is the surface glycoprotein that forms the spikes on the virion and is the effector for receptor binding and membrane fusion (Refs 15, 16) . GP is synthesised as a precursor molecule, GP 0 ; this is postranslationally cleaved by furin or a furin-like endoprotease into two subunits -GP 1 and GP 2 -which are linked by disulphide bonds to form a heterodimer (Refs 17, 18) . Homotrimers of GP 1 -GP 2 form the virion spikes. The primary gene product of the EBOV GP gene is not the GP, but rather a smaller nonstructural secreted GP (sGP), which is efficiently released from infected cells (Refs 19, 20) . The function of sGP has not been fully delineated, but it appears that expression of sGP might protect against cytotoxicity (Ref. 21) . VP40 functions as a matrix protein and is responsible for the formation of the filamentous particles (Ref. 22) . VP24 is a minor viral protein whose functions remain unknown, but recent data indicate that VP24 possesses structural features consistent with a function as a viral matrix protein and suggest that VP24 might have a role in viral assembly and budding (Refs 23, 24, 25) .
EBOV receptors and entry mechanism
The viral entry process consists of three sequential stages: attachment, co-receptor binding and fusion. Viral fusion can occur at the host cell plasma membrane or viruses can exploit the host cell's endocytic machinery to access the cytoplasm, depending on the characteristics of the viral fusion protein. 
EBOV replication and transcription
EBOV replication and transcription is described only briefly here; for a more detailed account, see relevant book chapters on this subject (Refs 13, 41). Replication and transcription of EBOV occurs exclusively in the host cell cytoplasm. Because the negative-strand EBOV RNA genomes cannot be employed as templates by the DNA-dependent RNA polymerases of the host cell, EBOV encodes its own RNA-dependent RNA polymerase, the L protein. The L protein is thought to control all catalytic functions that are required for replication and transcription. Fusion of the viral membrane with the host cell membrane releases the EBOV ribonucleoprotein complexes (the viral RNA and the proteins NP, VP35, VP30 and L) into the cytoplasm. The RNA genome is then transcribed into mRNAs to generate the EBOV proteins, while replication leads to synthesis of a replicative intermediate. This full-length antigenomic RNA, which is a copy of the negative-strand RNA genome, then functions as a template for EBOV RNA genome synthesis. Lastly, the nascent ribonucleoprotein complexes are assembled with EBOV structural proteins at the plasma membrane or intracellular membranes.
Animal models of EBOV HF
Animal models have been invaluable for studying the pathogenesis of numerous infectious diseases as well as for testing the efficacy of experimental prophylactic and therapeutic vaccine and/or drug regimens. The development of animal models for EBOV HF has been particularly challenging because the pathophysiology of human EBOV HF has not been clearly defined. This shortcoming is primarily due to the limited number of cases being managed in a medical setting equipped for both safe and exhaustive clinical laboratory evaluations.
Mice, guinea pigs, and several nonhuman primate species have been employed to model EBOV HF (reviewed in Refs 42, 43) . In addition to the encumbrances caused by a paucity of human data, comparison of the disease pathogenesis among these groups is difficult because of differences in age, route of infection, dose administered, and the nature of the challenge virus itself. As an example, the challenge dose appears to have a profound effect on the course of disease in nonhuman primates. Cynomolgus macaques exposed by intramuscular injection with a low challenge dose of ZEBOV [10 plaqueforming units (pfu)] succumbed to infection 8-12 days after challenge (mean = 9.8 days), whereas cynomolgus monkeys exposed by intramuscular injection to a high dose (1000 pfu) of the exact same ZEBOV isolate died 5-8 days after challenge (mean = 6.3 days) (Refs 44, 45). In human cases, route of infection ostensibly affects the disease course and the outcome. The mean incubation period for cases of ZEBOV known to be due to injection was 6.3 days, versus 9.5 days for contact exposures (Ref. 46) . Moreover, the case-fatality rate in this 1976 ZEBOV outbreak was 100% (85 of 85) in cases associated with injection compared with ~80% (119 of 149) in cases of known contact exposure (Ref. 46) . General features of disease pathogenesis associated with ZEBOV infection in mice, guinea pigs, and nonhuman primates are compared with human ZEBOV infection in Table 1 .
Rodents
Guinea pigs and mice have been the primary rodent models employed to study EBOV HF (Refs 47, 48, 49, 50 44, 48, 50, 51) . Also, bystander lymphocyte apoptosis, which is associated with human and nonhuman primate EBOV infections (Ref. 52) , has yet to be reported in EBOV-infected mice or guinea pigs (Refs 49, 50, 53), although a systematic investigation is needed to determine the incidence of lymphocyte apoptosis in the rodent models. Although the value of rodents for evaluating the efficacy of immune-and/or coagulationmodulating therapies is of course in doubt, these observations do not imply that rodent models of EBOV infection have no utility whatsoever. Rodents can serve an important role for evaluating the antiviral efficacy of candidate therapies against EBOV infection, and genetically engineered mice clearly have utility for evaluating specific hostpathogen interactions. b For animal models of ZEBOV HF, the time to death after experimental infection varies among studies and largely depends on the dose of ZEBOV employed. For human cases, information regarding time to death is difficult to assess because dose, route of exposure, and time of exposure are often unknown. In cases where route and time of exposure were documented, disease course appears to be more rapid in cases associated with injection than in cases of known contact exposure. c Bleeding manifestations in nonhuman primates and humans are infrequent and include bleeding of the gums, haematemesis, bleeding from the rectum and/or bloody stools, haematuria, epistaxis, and bleeding at puncture sites. Abbreviations: DIC, disseminated intravascular coagulation; IFN, interferon; IL, interleukin; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; NE, not systematically evaluated; TNF, tumour necrosis factor.
Nonhuman primates
Few studies have evaluated the pathogenesis of SEBOV in nonhuman primates (Refs 55, 69, 70 Coagulopathy is a prominent feature of EBOV infection of nonhuman primates. Some reviewers have argued that fibrin deposition is not ubiquitous in EBOV-infected primates, citing original studies (e.g. Refs 56, 57) reporting that both viral strain and nonhuman species can affect the prominence of fibrin deposits. However, the appearance of fibrin deposits is only one of several indicators of a dysregulated coagulation response. Other indicators of coagulopathy include consumption of clotting factors, increases in clotting times, increases in levels of fibrin degradation products, and thrombocytopaenia. A more extensive review of previous ZEBOV studies in nonhuman primates reveals evidence of coagulopathy in nearly every case, although those correlates can vary with species. For example, for ZEBOV-infected baboons, dramatic changes were noted in blood-clotting parameters, including marked increases in fibrin degradation products, but fibrin deposits were not a prominent feature (Ref. 57 ). This finding conclusively shows that elevated levels of fibrin were being formed at some point during the course of infection.
Pathogenesis of EBOV HF: the host response to infection
Understanding the kinetics of host-pathogen relationships, and identifying critical pathogenetic processes, are important for the rational development of therapeutic interventions. A model representing our current understanding of EBOV pathogenesis in primates is shown in Figure 1 . EBOV infection of humans and nonhuman primates is characterised by marked lymphopaenia and severe degeneration of lymphoid tissues (Refs 13, 61), and defects in the coagulation system. With a view to understanding these events, this section reviews the interactions between EBOV and the cells of lymphoid tissues, such as monocytes/macrophages, lymphocytes and dendritic cells, as well as cells that are important in maintaining the coagulation system, such as endothelial cells. 
EBOV and monocytes/macrophages

EBOV and lymphocytes
Despite the significant lymphocyte destruction associated with EBOV infections, lymphocytes do not support production of progeny virus (Refs 37, 52 
Effect of the pro-inflammatory response
Cytokines and chemokines are soluble proteins that are generated and secreted in response to an assortment of attacks on a host organism, including microbial infection. Cytokines and chemokines function in a pleiotropic manner, acting on many different types of cells to modulate the host's immune response. While cytokines and chemokines typically apply their antimicrobial actions locally, for example in areas of infection, cytokines and chemokines might also act systemically, and they commonly induce many of the symptoms of infection (e.g. fever, myalgia). 
Dysregulation of the coagulation system
Disseminated intravascular coagulation (DIC) is a syndrome characterised by systemic intravascular activation of coagulation leading to widespread deposition of fibrin in the vasculature, which contributes to the development of multiple organ failure (reviewed in Refs 103, 104) . DIC is associated with both bleeding and thrombotic abnormalities, and, in fact, widespread thrombosis and bleeding commonly occur simultaneously. Although DIC is often viewed as a prominent manifestation of EBOV infection in primates, the presence of DIC in human filoviral infections has been a controversial topic; cultural mores and logistical problems have hampered 
Clinical implications/applications
There are no known effective treatments for human filoviral infections. At this time, treating patients infected with EBOV essentially consists of intensive supportive care. Progress to develop therapies/treatments has been encumbered primarily because these viruses require special containment (Biosafety Level 4) for safe research, but also as a result of the sporadic and transitory nature of filoviral outbreaks and confinement to remote geographic locales. Nonetheless, there have been a number of attempts in clinical settings to improve the status of infected patients, and several strategies have been developed and tested in animal models ( Table 2 ). The treatment strategies are best analysed when broken down into the themes of direct antiviral approaches versus strategies to modulate the host immune response. 
Antiviral approaches Neutralisation of virus
Inhibition of membrane fusion
Maturation inhibitors Furin inhibitors
In vitro data sparse but not encouraging. More studies needed to evaluate potential. Approval for HIV therapy in humans shows in vivo feasibility.
Budding inhibitors
In vitro data sparse but not encouraging. More studies needed.
Modulation of the host immune response
Inflammatory response modulators Type I IFNs Treatment encouraging in rodents, but failed to protect nonhuman primates from lethal ZEBOV HF. Improvement of formulations and selective use of IFN-α subtypes with greater antiviral properties might have more utility.
SAH inhibitors
Adenosine analogues, but efficacy in mice linked to induction of type I IFN response. Failed to protect nonhuman primates from lethal ZEBOV HF. Anticytokine therapies Abnormal production of cytokines/chemokines is a notable feature of disease in EBOV-infected primates. Anticytokine therapies used for several human diseases and conditions present opportunities.
Inhibitors of
Problem will be specifically targeting approach to protect lymphocytes lymphocyte apoptosis without concurrently enhancing survival of EBOV-infected cells.
Coagulation modulators
Tissue factor pathway Pilot study in small cohort of rhesus monkeys showed partial protection, inhibitors and delayed death in unprotected animals. Might have greatest utility in combinatorial approaches and/or in supportive care. Factor X inhibitors Blocking common pathway might be more beneficial than inhibiting a specific coagulation pathway. Success in treating deep-vein thrombosis with factor X inhibitors in humans shows potential for mitigating effects of EBOV HF. Activated protein C Reduced levels of plasma protein C in ZEBOV-infected nonhuman primates mirrors reduced levels associated with human sepsis. Success in treating human sepsis with a recombinant product indicates possible utility for EBOV HF.
Therapeutic vaccines Vesicular stomatitis virus-based ZEBOV vaccine showed promising results when administered therapeutically to mice. Confirmatory studies in nonhuman primates are critically needed to determine utility for future development.
Combination therapies
Difficulty in protecting nonhuman primates using a variety of approaches suggests that improved survival might be realised by combining strategies that suppress viral replication with strategies that modulate inflammation and coagulation, allowing the host time to mount an effective immune response. 
Inhibition of transcription and replication
Modulation of the host immune response
Regulation of the pro-inflammatory response
The other primary theme for treatment of EBOV infections has been modulation of the host immune response. This area has primarily involved efforts to boost innate immunity. Other approaches to modulation of the host immune response include strategies to offset or moderate the physiological effects of disease. Pretreating rhesus monkeys with antioxidants, such as vitamin E, failed to confer any beneficial or protective effect to ZEBOV-infected rhesus monkeys (Ref. 64 ).
Regulation of the coagulation system
Two patients infected with MARV in 1975 were given vigorous supportive treatment and prophylactic heparin (Ref. 127). As both patients survived infection, heparin treatment was attempted on a single patient during the original outbreak of ZEBOV in 1976 (Ref. 2). Unfortunately, there was no favourable outcome in this case. As noted above, ZEBOV infection induces overexpression of the procoagulant TF in primate monocytes/macrophages (Ref. 63) , suggesting that TF-pathway inhibition might ameliorate the effects of EBOV HF. Based on these data, it was postulated that blocking factor VIIa (FVIIa)/TF might be beneficial after EBOV infection (Ref. 65 ). In a preliminary study, nine ZEBOV-infected monkeys were treated with a protein that prevents blood clotting -recombinant nematode anticoagulant protein c2 (rNAPc2) -while three ZEBOV-infected monkeys were given a placebo control. Three of the nine treated animals survived, whereas all three animals that were given the placebo control died. Importantly, EBOV infection is nearly 100% fatal in monkeys and kills up to 90% of humans infected with the virus, so a 33% survival rate for one of the most virulent diseases known is significant and represents a key breakthrough. Other coagulation defects associated with EBOV infection of primates include thrombocytopaenia (Refs 13, 61), although the mechanism for this anomaly has not been defined. Pretreating rhesus monkeys with thromboxane inhibitors or prostacyclin to counteract platelet aggregation failed to confer any beneficial or protective effect to ZEBOVinfected rhesus monkeys (Ref. 64 ).
Research in progress and outstanding research questions Antibody therapy
Passive transfer of neutralising antibodies protects mice, guinea pigs and hymadryad baboons from EBOV infection. However, passive immunotherapy in monkeys of the genus Macaca has been extremely disappointing. Recent data indicate that high levels of shed GP are present in the blood of EBOV-infected animals, suggesting that circulating GP might play an important role in disease pathogenesis by blocking the activity of EBOV-neutralising antibodies (Ref. 120) . Although previous attempts were not completely successful in macaques, several new approaches warrant investigation before passive transfer of antibodies is abandoned as a potential therapy for EBOV HF. The availability of EBOV-immune monkeys, and the development of improved electrophoresis-based separation technologies, should facilitate the preparation of high-quality hyperimmune reagents. Passive therapy using homologous hyperimmune plasma should afford the opportunity to achieve much higher circulating antibody concentrations, which are likely necessary to offset the extreme viraemia observed in the nonhuman primate models of EBOV HF. Recently, there has been discussion about the role of antibodies in enhancing EBOV infection and potentially exacerbating disease (Refs 128, 129, 130) . Although the significance of immunological enhancement has yet to be documented in vivo, any such demonstration would clearly require a re-evaluation of immunotherapeutic strategies.
RNA interference
Small interfering RNAs (siRNAs) are powerful, sequence-specific reagents designed to suppress the expression of genes in cultured mammalian cells through the process of RNA interference (RNAi) (Refs 131, 132) . The small size of siRNAs, compared with traditional antisense molecules, prevents activation of the mammalian dsRNAinducible IFN system. These complexes recognise their single-stranded mRNA targets by matching RNA sequences, and direct the cleavage and destruction of any mRNAs that perfectly match one of the duplex siRNA strands, thereby preventing mRNA translation. Intracellular silencing complexes can be generated either by exogenously administered siRNA duplexes or by siRNAs processed from precursor short-hairpin (sh) RNAs expressed in the nucleus by vectorbased systems (Refs 133, 134, 135 Although there have been no published studies evaluating the efficacy of RNAi as a strategy for suppressing EBOV replication either in vitro or in vivo, development and optimisation of this technology might lead to useful and effective treatments against EBOV HF. Indeed, the utility of this approach as an effective strategy to combat EBOV HF will depend on overcoming a number of obstacles, in particular the ability to develop an efficient drug delivery system. Progress is being made in this area, as evidenced by the recent work of Ge et al. illustrating the ability of polyethyleneimine (PEI), a cationic polymer, to promote the successful delivery of siRNA by intravenous administration in influenza-virusinfected mice (Ref. 135 ).
Budding inhibitors
EBOV budding is mediated by two proline-rich motifs -PPxY and PTAP -within VP40 ( Refs 136, 137, 138, 139, 140) . A full N-terminus of VP40 is required for budding to occur efficiently (Refs 137, 139) . Optimal budding is facilitated by interaction with the cellular ubiquinating enzymes Nedd4 and Tsg101 (Refs 138, 139, 140) . Thus, drugs that interfere with these interactions are of obvious interest. However, identifying compounds that have therapeutic utility will be challenging, because it is likely that concentrations required to attain sufficient inhibition would be difficult to realise in sera of test animals. Furthermore, the utility of budding inhibitors as potential therapies is called into question by recent work reported by Ebihara and colleagues (Ref. 141) . Specifically, rescue of ZEBOVs containing mutations in the late domains of VP40 resulted in viral yields that were only 1.5 log10 pfu/ml less than wild-type ZEBOV; it is unlikely that such reduction would have much therapeutic benefit, considering the extremely high viral loads attained during in vivo ZEBOV infections (Ref. 61) .
Immune modulators IFNs
The use of IFN-α and inducers of type I IFNs as a therapy for treating EBOV infection has been largely unsuccessful thus far. However, an increased understanding of EBOV pathogenesis concomitant with recent advances in the production of alternative IFN therapeutic preparations might offer improved efficacy. 
Anticytokine interventions
There have been relatively few attempts to modulate the dysregulated cytokine/chemokine response that is a consistent feature among many of the viral HFs. Treating MARV-infected guinea pigs with desferal, an immunomodulator that is an IL-1 and TNF-α antagonist, partially protected a small cohort of animals (Ref. Additional benefits might be realised by using drugs that target NF-κB activity because many of these cytokines/chemokines can be upregulated by NF-κB.
Inhibition of apoptosis of bystander lymphocytes
It is likely that the marked apoptosis of bystander lymphocytes contributes to the immunosuppression that characterises EBOV infection of primates. Therefore, successful inhibition of bystander lymphocyte apoptosis offers an attractive therapeutic target for mitigating the lethal effects of EBOV HF. The exact mechanism(s) for triggering apoptosis pathways activated during EBOV infection of primates remains unknown. Although it will be important to determine whether EBOV proteins exhibit pro-apoptotic activities, it is clear that increased expression of pro-apoptotic genes such as TRAIL and Fas during EBOV infections are contributing factors to the observed lymphocyte apoptosis and thus are obvious targets for intervention strategies. Therapies directed to inhibit Fas and/or TRAIL function might have a beneficial effect. These therapeutic interventions are currently being tested in other disease models. For example, treatment using a neutralising anti-TRAIL monoclonal antibody in HIV-infected mice significantly reduced the development of apoptotic CD4 + T cells (Ref. 149 ). Caspase inhibitors have also shown some benefit in murine models of sepsis (Ref. 150) . However, the targeted blockade of apoptosis to lymphocytes, and not to cell populations that harbour EBOV, is a formidable hurdle that must be overcome before this therapeutic strategy can be fully realised.
Coagulation modulators
Dysregulation of the coagulation system appears to be important to the development of haemorrhagic shock and death in fatal cases of ZEBOV. The first therapeutic treatment for EBOV HF was recently demonstrated in nonhuman primates (Ref. 65) . This treatment regimen was based on targeting the mechanism by which the coagulation cascade was activated during EBOV HF. In particular, identifying the importance of the TF pathway provided a rational approach to identify and utilise rNAPc2 in an attempt to mitigate the severe effects of EBOV infection. As rNAPc2 primarily targets signalling through the extrinsic blood coagulation pathway, additional benefits might be realised by using inhibitors of FX to target the intrinsic pathway as well.
In other recent studies, we showed rapid drops in levels of plasma protein C in ZEBOV-infected nonhuman primates, with the initial decrease observed as early as the first day after ZEBOV challenge (Ref. 63 ). This work suggests that protein C might be a critical component to the observed coagulation dysfunction in ZEBOV HF. The protein C system is one of the main anticoagulant mechanisms in blood (Ref. 151) . Growing evidence also suggests that protein C has direct anti-inflammatory properties and modulating activity on cellular functions, likely by blocking NF-κB nuclear translocation (Ref. 152) . Reduced levels of protein C are found in the majority of patients with sepsis and are associated with an increased risk of death (Ref. 153) . From a therapeutic perspective, treatment with recombinant human activated protein C significantly reduced mortality in patients with severe sepsis (Ref. 154) . Clearly, identifying protein C abnormalities in primate models of EBOV HF (which so closely parallel protein C anomalies in human coagulopathies) offers an ideal target for chemotherapeutic interventions.
Therapeutic vaccines
Recently, significant progress was made towards the development of an EBOV vaccine. Thus far, three EBOV vaccine platforms have been tested successfully in nonhuman primates: (1) a primeboost strategy consisting of a DNA vaccine prime followed by an adenovirus (ADV) vaccine boost (Ref. 159) . They noted that the rapid release of pro-inflammatory cytokines in asymptomatic ZEBOV infections suggests that this response might be involved in controlling viral replication and inducing specific immunity. If the outcome of EBOV infection is mostly determined by host responses during the early stages of the incubation period, then interventions to augment those defences, such as therapeutic vaccines, might help to prevent or ameliorate the disease.
Concluding remarks
There is a critical need for the development of effective therapies to respond to outbreaks of EBOV in Africa and to counter potential acts of bioterrorism. In addition, a potential EBOV exposure involving a researcher at a US Army laboratory (Ref. 160) , and the recent death of a Russian scientist after an accidental exposure to EBOV (Ref. 161), emphasise the need for medical countermeasures for postexposure prophylaxis.
Considering the aggressive nature of EBOV infections, in particular the rapid and overwhelming viral burdens, early diagnosis will play a significant role in determining the success of any intervention strategy. Thus far, antiviral modalities targeting EBOV replication have largely been unsuccessful. Strategies showing some promise in rodents have uniformly failed to protect nonhuman primates from lethal EBOV HF (Refs 58, 59, 111, 112, 116, 123, 124, 125, 126) . Currently, among the most promising antiviral approaches are siRNAs. Assessment of this approach in in vivo models hinges on the ability to develop an efficient drug delivery system, and an intense effort is under way towards achieving this goal.
Results of in vivo studies performed to date suggest that there might be no single treatment to combat the lethal effects of EBOV HF. Successful treatment might require combining several beneficial approaches, such as strategies targeting viral replication with modalities controlling the manifestations of disease. A beneficial effect using an inhibitor, rNAPc2, of the TF pathway has been observed (Ref. 65 ). It will be important to determine whether survival can be improved by combining coagulation-modulating agents such as rNAPc2 with agents that have antiviral properties. Moreover, it will be important to evaluate whether recombinant activated protein C provides synergistic benefit with other coagulation-modulating agents, such as rNAPc2. Therapeutic vaccines might also have utility in combination approaches. In some cases, therapeutic vaccines are administered in conjunction with other treatments including immune globulin to improve efficacy (reviewed in Ref. 156). It will be interesting to determine whether the therapeutic efficacy of rNAPc2 can be improved by employing this anticoagulant protein in combination with therapeutic vaccines. Clearly, an increased understanding of the mechanisms of EBOV pathogenesis will facilitate our ability to develop effective countermeasures against this notoriously aggressive pathogen.
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